Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thorsten Stiewe

Showing results (61-70 of 167) with videos related to

Pageof 17
Sort By:
Seminars in Cancer Biology|May 11, 2026
Tumor microenvironment evaluation in lung cancer: Spatio-temporal dynamics and clinical implicationsSelma Dizdarević, Oleg Timofeev, Daniel Kazdal, et al.
BMC Genomics|March 23, 2017
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patientsTill Adhikary, Annika Wortmann, Florian Finkernagel, et al.
Plos Genetics|August 23, 2013
Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functionsKatharina Schlereth, Charlotte Heyl, Anna-Maria Krampitz, et al.
Cancers|July 3, 2019
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase <i>CA2</i> Gene as Resistance FactorRicarda Hannen, Martin Selmansberger, Maria Hauswald, et al.
Journal of the National Cancer Institute|June 12, 2008
KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatmentMargarete Schön, B Gregor Wienrich, Susanne Kneitz, et al.
Molecular & Cellular Proteomics : MCP|November 17, 2017
Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer MicroenvironmentThomas Worzfeld, Florian Finkernagel, Silke Reinartz, et al.
The EMBO Journal|February 2, 2008
p73 poses a barrier to malignant transformation by limiting anchorage-independent growthMichaela Beitzinger, Lars Hofmann, Claudia Oswald, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 2, 2022
Partial p53 reactivation is sufficient to induce cancer regressionBoris Klimovich, Laura Meyer, Nastasja Merle, et al.
Cell Death & Disease|February 26, 2026
Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapoptDanai Mavridi, Julianne S Funk, Dimitrios-Ilias Balourdas, et al.
Scientific Reports|September 23, 2025
Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemiaCharlotte Sommer, Hildegard I D Mack, Madeleine C Killer, et al.
Pageof 17

Showing results (61-70 of 167) with videos related to

Sort By:
Pageof 17
Seminars in Cancer Biology|May 11, 2026
Tumor microenvironment evaluation in lung cancer: Spatio-temporal dynamics and clinical implicationsSelma Dizdarević, Oleg Timofeev, Daniel Kazdal, et al.
BMC Genomics|March 23, 2017
Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patientsTill Adhikary, Annika Wortmann, Florian Finkernagel, et al.
Plos Genetics|August 23, 2013
Characterization of the p53 cistrome--DNA binding cooperativity dissects p53's tumor suppressor functionsKatharina Schlereth, Charlotte Heyl, Anna-Maria Krampitz, et al.
Cancers|July 3, 2019
Comparative Transcriptomic Analysis of Temozolomide Resistant Primary GBM Stem-Like Cells and Recurrent GBM Identifies Up-Regulation of the Carbonic Anhydrase <i>CA2</i> Gene as Resistance FactorRicarda Hannen, Martin Selmansberger, Maria Hauswald, et al.
Journal of the National Cancer Institute|June 12, 2008
KINK-1, a novel small-molecule inhibitor of IKKbeta, and the susceptibility of melanoma cells to antitumoral treatmentMargarete Schön, B Gregor Wienrich, Susanne Kneitz, et al.
Molecular & Cellular Proteomics : MCP|November 17, 2017
Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer MicroenvironmentThomas Worzfeld, Florian Finkernagel, Silke Reinartz, et al.
The EMBO Journal|February 2, 2008
p73 poses a barrier to malignant transformation by limiting anchorage-independent growthMichaela Beitzinger, Lars Hofmann, Claudia Oswald, et al.
Journal of Experimental & Clinical Cancer Research : CR|March 2, 2022
Partial p53 reactivation is sufficient to induce cancer regressionBoris Klimovich, Laura Meyer, Nastasja Merle, et al.
Cell Death & Disease|February 26, 2026
Targeting the p53 cancer mutants Y220C, Y220N, and Y220S with the small-molecule stabilizer rezatapoptDanai Mavridi, Julianne S Funk, Dimitrios-Ilias Balourdas, et al.
Scientific Reports|September 23, 2025
Detection of minimal residual disease in circulating cell-free DNA in acute myeloid leukemiaCharlotte Sommer, Hildegard I D Mack, Madeleine C Killer, et al.
Pageof 17